Exosomal Secretion of Cytoplasmic Prostate Cancer Xenograft-derived Proteins* S

Flip H. Jansen†, Jeroen Krijgsfeld§, Angelique van Rijswijk‡, Gert-Jan van den Bemd‡, Mirella S. van den Berg‡, Wytse M. van Weerden‡, Rob Willemsen¶, Lennard J. Dekker∥, Theo M. Luider∥, and Guido Jenster‡**

Novel markers for prostate cancer (PCa) are needed because current established markers such as prostate-specific antigen lack diagnostic specificity and prognostic value. Proteomics analysis of serum from mice grafted with human PCa xenografts resulted in the identification of 44 tumor-derived proteins. Besides secreted proteins we identified several cytoplasmic proteins, among which were most subunits of the proteasome. Native gel electrophoresis and sandwich ELISA showed that these subunits are present as proteasome complexes in the serum from xenograft-bearing mice. We hypothesized that the presence of proteasome subunits and other cytoplasmic proteins in serum of xenografted mice could be explained by the secretion of small vesicles by cancer cells, so-called exosomes. Therefore, mass spectrometry and Western blotting analyses of the protein content of exosomes isolated from PCa cell lines was performed. This resulted in the identification of mainly cytoplasmic proteins of which several had previously been identified in the serum of xenografted mice, including proteasome subunits. The isolated exosomes also contained RNA, including the gene fusion TMPRSS2-ERG product. These observations suggest that although their function is not clearly defined cancer-derived exosomes offer possibilities for the identification of novel biomarkers for PCa. Molecular & Cellular Proteomics 8: 1192–1205, 2009.

For several decades now, prostate-specific antigen (PSA) has been utilized as the “gold standard” biomarker for the detection of prostate cancer (PCa) (1). Its introduction caused a dramatic decrease in the prevalence of advanced stages of PCa (2). However, ongoing efforts are being made to discover new biomarkers for PCa because it became clear that PSA has limited diagnostic specificity and prognostic value, leading to an enormous increase in unnecessary biopsies and overtreatment of low risk PCa patients (3).

In the last decades, many alternative diagnostic or prognostic markers for PCa have been proposed on protein as well as on RNA and genomic levels. Examples of alternative markers on the protein level are numerous, including various PSA isoforms, prostate stem cell antigen, human kallikrein 2, early prostate cancer antigen, and α-methylacyl-CoA racemase (4–8). On the RNA level, the PCA3 test and especially the recently discovered fusion of TMPRSS2 with ETS transcription factors may hold promise for PCa detection and potentially prognosis in the near future (9, 10). One of the drawbacks of the latter two as markers for PCa is the fact that they are detected in urine, after a standardized prostatic massage, instead of in serum or plasma. This will hamper retrospective validation as most historical biorepositories do not contain urine. Although several validation studies of promising candidates have been performed in the past or are currently underway, no single marker has yet outperformed PSA, justifying ongoing efforts in searching for PCa biomarkers.

One approach is the screening of large series of serum samples from men with and without PCa. However, given the large sample variability, the high complexity, and dynamic range of proteins in serum samples, large numbers of human serum samples have to be analyzed to achieve any statistical significance. Also identified proteins may be related to secondary body defense mechanisms rather than being directly derived from the tumor cells as are most tumor markers applied in the clinic today. To circumvent these problems, we have exploited the xenograft model system as a platform for the discovery of new biomarkers for PCa (11). As has recently been reported, this model system is indeed capable of identifying human proteins that are shed into the circulation by human prostate cancer cells (12).

In the present study we further exploited this approach and performed an in-depth proteomics analysis of serum of mice carrying androgen-sensitive (PC346) or androgen-independent prostate cancer xenografts (PC339). Among the discovered human proteins were numerous cytoplasmic proteins,
which such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), lactate dehydrogenases A and B, and various subunits of the proteolytic proteasome complex (12). Many of these cytoplasmic proteins are also present in the human plasma proteome as retrieved from the database of the Human Proteome Organisation Plasma Proteome Project (13).

We hypothesized that the presence of cytoplasmic tumor-derived proteins in the xenograft sera could be explained by the secretion of exosomes. Exosomes are small membrane vesicles secreted by virtually every cell type, including tumor cells (14). Exosomes are formed in multivesicular bodies by inward budding, thereby encapsulating cytoplasmic components (14, 15). The exact function of exosomes in tumor cells has yet to be elucidated but is expected to relate to roles in cell-to-cell contact, tumor-stroma interaction, protein degradation, and antigen presentation (14, 15). In addition to containing proteins, it was recently discovered that exosomes also contain functional RNA, proposed as “exosomal shuttle RNA” (16).

To confirm our hypothesis that the cytoplasmic tumor-derived proteins in the serum of xenograft-bearing mice were the result of exosomal secretion, we isolated exosomes from the PC346C cell line and analyzed their protein content. To further explore the contents of exosomes we isolated and analyzed exosomal RNA from both the PC346C and VCaP cell lines.

**EXPERIMENTAL PROCEDURES**

**Xenograft Serum Collection—**Human prostate cancer xenografts were grown on immune-incompetent mice athymic male nude (nu/nu) BALB/c mice (n = 9 for each xenograft; Taconic, Ry, Denmark) (11, 12). We used the human prostate cancer cell lines PC346 (androgen-sensitive) and PC339 (androgen-independent). Specific characteristics have been described previously (17). Prior control serum was collected by retro-orbital puncture. Tumor-bearing mice were sacrificed after 4–5 weeks, and blood was collected. Samples were stored at −80 °C. The protocol was approved by the Animal Experiments Committee under the national Experiments on Animals Act and adhered to the rules laid down in this national law that serves the implementation of “Guidelines on the protection of experimental animals” by the council of Europe under Directive 86/609/EC.

**Preparation of Xenograft Sera for Mass Spectrometry—**After filtration using a 0.22-μm spin filter, high abundance proteins were removed utilizing Multi Affinity Removal Spin cartridges (Agilent Technologies, Wilmington, DE) according to the manufacturer’s instructions. Depleted samples were concentrated on 5-kDa-cutoff ultracentrifugation columns (Agilent Technologies). Total protein concentration was collected by the Bradford method (Bio-Rad). Precast 4–20% polyacrylamide linear gradient gels (Bio-Rad) were utilized to separate 10 μg of protein of depleted mouse serum (pooled from nine individual control mice, nine PC339 xenograft-bearing mice, or nine PC346 xenograft-bearing mice) by SDS-PAGE (Mini-Protean III, Bio-Rad). Prestained high range molecular weight markers (SeeBlue, Invitrogen) were loaded on each gel. After running, gels were stained by Coomassie Brilliant Blue (Merck).

Gel lanes (range, 5–200 kDa) were excised and divided into 3-mm sections. Gel slices were washed, destained twice (50% (v/v) acetonitrile in 50 mM ammonium bicarbonate), dehydrated (100% acetonitrile), and reduced with 6.5 mM DTT in 50 mM ammonium bicarbonate for 1 h at 37 °C. After alkylation with 54 mM iodoacetamide in 50 mM ammonium bicarbonate, proteins were dehydrated in 100% acetonitrile and then rehydrated with the digestion solution containing 10 ng/μl ultra grade sequencing trypsin (Promega, Madison, WI) for 30 min at room temperature. After addition of 30 μl of 50 mM ammonium bicarbonate solution, gel particles were incubated overnight at 37 °C. The peptides were extracted using 0.5% formic acid in 50% acetonitrile, dried completely in a vacuum centrifuge, and stored at −80 °C until analysis.

**Liquid Chromatography-Mass Spectrometry of Xenograft Sera—** Nanoflow LC-tandem mass spectrometry was performed for samples by coupling an Agilent 1100 HPLC system (Agilent Technologies), operated as described previously (12), to a 7-tesla LTQ-FIT mass spectrometer (FT-ICR-MS, Thermo Electron, Bremen, Germany). For protein identification, database searches were performed using Mascot version 2.0 (Matrix Science, London, UK) allowing 5-ppm mass deviation for the precursor ion, a 0.6-Da tolerance on the fragment ions, and trypsin as the digestion enzyme. A maximum number of one missed cleavage was allowed, and carbamidomethylated cysteine and oxidized methionine were set as fixed and optional modifications, respectively. Only peptides with Mascot scores >30 were accepted. Scaffold (version 01_05_06, Proteome Software Inc., Portland, OR) was used to validate MS/MS-based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than 90.0% probability as specified by the Peptide Prophet algorithm (18). Protein identifications were accepted if they could be established at greater than 95.0% probability and contained at least two identified peptides. Protein probabilities were assigned by the Protein Prophet algorithm (19). Before we annotated a certain peptide derived from the xenograft-bearing mice as human, a stringent selection procedure was followed (see Fig. 1). First all peptide mass values identified in the serum from control mice and PC339 or PC346 xenograft-bearing mice were searched against both the International Protein Index (IPI) mouse and IPI human databases (version 3.18, containing 53,788 and 60,090 proteins, respectively). Then a selection was made of peptides uniquely present in the serum of PC346 or PC339 xenograft-bearing mice. These peptides were subsequently divided into a group of human-specific peptides (identified only in the IPI human database) and a group of homologous peptides (present in both the IPI human and IPI mouse databases). Homologous peptides were annotated as tumor-derived if four or more times higher abundant in the serum of PC339 or PC346 xenografted mice in comparison with control serum as listed in Scaffold. Additionally to double check human specificity, the identified human-specific peptides were blasted against the Swiss-Prot database of the National Center for Biotechnology Information (NCBI) database.

**Two-dimensional SDS-PAGE Analysis of Proteosomes—**To clean up samples from contaminants, for each xenograft-derived serum sample (50 μg of protein) the 2-D Clean-Up kit (Amersham Biosciences) was utilized according to the manufacturer’s instructions. Next samples were solubilized in 125 μl of rehydration buffer (8 M urea, 2% CHAPS, 0.5% IPG buffer, 0.2% DTT, trace of bromphenol blue, all dissolved in H2O). The samples were loaded onto Immobiline dry strip gels (pH 3–10, non-linear, 7 cm; Amersham Biosciences). Isoelectric focusing was carried out as follows: 30 V for 10 h, 300 V for 2 h, 1000 V for 30 min, 5000 V for 90 min, 5000 V for 30 min, and 20 V for 20 h. Before starting the second dimension, strips were reduced and alkylated for 15 min in DTT equilibration buffer (6 M urea, 50 mM Tris, pH 8.8, 20% glycerol, 2% SDS, 1% DTT) and iodoacetamide equilibration buffer (6 M urea, 50 mM Tris, pH 8.8, 20% glycerol, 2% SDS, 2.5% iodoacetamide). Next the IPG strips were placed upon a Criterion XT bis-Tris gel (12%; Bio-Rad). The second dimension was run at 100 V for ±2 h with XT MOPS buffer (Bio-Rad). After running the second dimension, gels were blotted onto Protran nitrocellulose membrane in Tris-glycine-SDS buffer (Bio-Rad). The immunoblot was...
Exosomes Secrete Cytoplasmic Prostate Cancer Proteins

blocked for 1 h and after washing twice incubated overnight at 4 °C with a monoclonal antibody (1:2000) against proteasome α subunits 6, 2, 4, 5, 1, and 3 (clone MCP231, Biomol International, Exeter, UK). This corresponds with the α subunits 1, 2, 3, 5, 6, and 7 according to the nomenclature of Baumeister et al. (20). In addition, monoclonal antibodies specifically directed against the proteasome α1 subunit (PSMA1; α6 according to the Baumeister et al. (20) nomenclature) (clone MCP20, Biomol International) or α3 subunits (PSMA3; α7 according to the Baumeister et al. (20) nomenclature) (clone MCP72, Biomol International) were utilized. The immunoblot was washed and incubated for 1 h with a 1:1000 solution of a goat anti-mouse horseradish peroxidase-conjugated antibody (DakoCytomation, Glostrup, Denmark). The secondary antibody was visualized with a chemiluminescence detection kit (Roche Applied Science). For reprobing, blots were immersed in a 0.04 M Tris-HCl, 0.06 M Tris base, 0.07 M SDS, 0.1 M β-mercaptoethanol solution for 20 min at 50 °C.

Native Gel Electrophoresis of Proteasomes—The protocol for characterization of the proteasome by native gel electrophoresis was followed as previously described by Elsasser et al. (21). Depleted xenograft and control serum samples were mixed with 5× sample buffer containing 250 mM Tris-HCl, pH 7.4, 50% glycerol, 60 mM xylene cyanol. Samples were either directly loaded or denatured by heating at 96 °C for 5 min. Gels were run for 3–4 h at 4 °C. Gels were transferred onto Protran nitrocellulose membranes at 250 mA for 1.5 h.

Sandwich ELISA for Quantification of the Proteasome—Serum proteasome concentrations were measured as previously described by Dutaud et al. (22) with some minor modifications. Briefly serum from control (n = 3) and PC339 (n = 3) or PC346 (n = 3) xenograft-bearing mice (1:20 diluted) was incubated for 1 h on a plate coated with a 1:4500 dilution of a monoclonal antibody against PSMA1 (clone MCP20, Biomol International). After addition of a 1:1500 solution of a rabbit anti-proteasome antibody (directed against β subunits of the proteasome; PW 8155, Biomol International) cells were extensively washed with PBS-Tween 20 buffer. Then a 1:4000 solution of goat anti-rabbit horseradish peroxidase-conjugated antibody (DakoCytomation) was added, and the plate was incubated for 1 h in the dark. To reveal horseradish peroxidase activity, 50 mM phosphate, 25 mM citrate buffer, pH 5.0 was added to the cells. After 15 min, the reaction was stopped with 2.5 M sulfuric acid. Absorbance values were measured at 492 nm. All analyses were performed in triplicate.

Cell Culture and Isolation of PC346C and VCaP-derived Exosomes—The human prostate cancer cell line PC346C was cultured in Dulbecco’s modified Eagle’s medium-Ham’s F-12 medium (Cambrex Bio Science, Verviers, Belgium) supplemented with 0.1 mM R1881, 2% FCS (PAN Biotech, Aidenbach, Germany), 1% insulin-transferrin-serum-lecithin (Invitrogen), 0.01% BSA (Roche Applied Science), 10 ng/ml epidermal growth factor (Sigma-Aldrich), 100 units/ml penicillin and 100 µg/ml streptomycin antibiotics (Cambrex Bio Science), 100 ng/ml fibronectin (Harbor Bio-Products, Tewu-bio, the Netherlands), 20 µg/ml feticin (ICN Biomedicals, Zuerthemer, The Netherlands), 50 ng/ml chloro toxin (Sigma-Aldrich), 0.1 mM phosphoethanolamine (Sigma-Aldrich), and 0.6 ng/ml triiodothyronine (Sigma-Aldrich) (23). The human PCA cell line VCaP was cultured in RPMI 1640 medium (Cambrex Bio Science) supplemented with 10% dextran-coated charcoal-treated FCS (PAN Biotech) and 100 units/ml penicillin and 100 µg/ml streptomycin antibiotics (Cambrex Bio Science). Exosomes were isolated according to the protocol described previously by Hegmans et al. (24). Briefly PC346C and VCaP were cultured in their respective medium to 80% confluency. Cultures were washed twice with PBS and incubated for 48 h in a humidified atmosphere of 5% CO2, 95% air with serum-free medium consisting of Dulbecco’s modified Eagle’s medium-Ham’s F-12 or RPMI 1640 medium (Cambrex Bio Science) supplemented with 0.1 mM R1881. After incubation cell culture supernatants were subjected to successive centrifugations of 400 × g (10 min), 3000 × g (20 min), and 10,000 × g (30 min). Exosomes were then pelleted at 64,000 × g for 110 min using an SW28 rotor (Beckman Coulter Instruments, Fullerton, CA). Exosome pellets were resuspended in 0.32 M sucrose and centrifuged at 100,000 × g for 1 h (SW60 rotor, Beckman Coulter Instruments).

For several experiments, the isolated exosomes from PC346C were further purified by immobilization onto magnetic beads. In short, 25 µl of Dynabeads, precoated with goat anti-mouse immune globulin G (Invitrogen Dynal AS, Oslo, Norway) were incubated for 1 h with 30 µl of an anti-CD9 monoclonal antibody (clone MM2/57, Chemicon International, London, UK). Thereafter beads were incubated by rotation top end over with 20 µg of exosomes for 1 h at 4 °C. After washing four times, beads and exosomes were resuspended in PBS for further experiments.

Electron Microscopy of Isolated Exosomes—Exosomes from PC346C obtained after ultracentrifugation of cell culture supernatants were resuspended in 10 µl of Milli-Q and spotted onto Formvar-coated grids (200 mesh). Adsorbed exosomes were fixed in 2% paraformaldehyde for 5 min at room temperature. After fixation the exosomes were either directly negatively stained using uranyl acetate or immunolabeled with antibodies against CD9 (clone MM2/57, Chemicon International). Antigen-antibody complexes were visualized with protein A conjugated with 10-nm colloidal gold particles (1:20 dilution; Aurion, Wageningen, The Netherlands) followed by negative staining (see above). The specificity of the labeling procedure was tested by omitting the primary antibody. Grids were examined by a Philips CM100 electron microscope at 80 kV.

Mass Spectrometry of Exosomes—After resuspending the exosome pellet in PBS, 10 µg of isolated exosomes and 10 µg of supernatant fraction were applied onto two 10% SDS-polyacrylamide gels. After running, one of the gels was silver-stained as described previously by Mortz et al. (25). This gel was used to identify distinct bands present in the exosome fraction (see Fig. 4b). Subsequently these bands were excised from a Coomassie Brilliant Blue (Merck)-stained gel and cut in 3-mm sections. Preparation for mass spectrometry was performed using the protocol described under “Preparation of Xenograft Sera for Mass Spectrometry”. Peptide separation was performed on a nanoscale liquid chromatography system (nanoLC Ultimate 3000) (Dionex, Sunnyvale, CA) with a 50-min gradient (5–40% acetonitrile, H2O, 0.1% formic acid). The injection volume was 5 µl of the tryptically digested sample. Peptides were separated on a C18 PepMap column (150 mm × 75 µm inner diameter) (Dionex) at 200 nl/min after preconcentration on a trap column (1 mm × 300 µm inner diameter). Separated peptides were detected by a linear ion trap Orbitrap (LTQ-Orbitrap) mass spectrometer (Finnigan LTQ Orbitrap XL, Thermo Electron). Samples were measured in a data-dependent acquisition mode. In the measurement method used, the peptide masses are measured in a survey scan at a maximum resolution of 60,000. To obtain a maximum mass accuracy a prescan is used to keep the ion population in the Orbitrap for each scan approximately the same. During the high resolution scan in the Orbitrap the five most intense monoisotopic peaks in the spectra were fragmented and measured in the LTQ. The fragment ion masses were measured in the LTQ to have a maximum sensitivity and a maximum amount of MS/MS data.

For a full analysis of the exosomal proteome, 10 µg of the isolated exosome fraction was applied onto a 10% SDS-polyacrylamide gel and run for ~1.5 cm inside the running gel. Thereafter this gel section was excised and divided into 3-mm sections, washed, destained (100% acetonitrile followed by 50 mM ammonium bicarbonate), dehydrated (100% acetonitrile), and reduced with 6.5 mM DTT in 50 mM ammonium bicarbonate for 45 min at 60 °C. After alkylation with 54 mM iodoacetamide in 50 mM ammonium bicarbonate, proteins were...
dehydrated in 100% acetonitrile and then rehydrated with the digestion solution containing 10 ng/μl ultra grade sequencing trypsin (Promega) for 30 min on ice. After removal of the redundant trypsin solution and addition of 50 μl ammonium bicarbonate solution to cover the gel pieces, gel pieces were incubated overnight at 37 °C. After extraction, the peptides were dissolved in 5% formic acid and stored at −80 °C until analysis. Mass spectrometry was performed using the protocol described under “Liquid Chromatography-Mass Spectrometry of Xenograft Sera.” For protein identification, database searches were performed using Mascot version 2.2 (Matrix Science) allowing 5-ppm mass deviation for the precursor ion, a 0.6-Da tolerance on the fragment ions, and trypsin as the digestion enzyme. A maximum number of one missed cleavage was allowed, and carbamidomethylated cysteine and oxidized methionine were set as fixed and optional modifications, respectively. All peptide mass values identified in the isolated exosomes were searched against the IPI human database (version 3.37, containing 69,164 proteins). Only peptides with Mascot scores >30 were accepted. Scaffold (version 2.0.12, Proteome Software Inc., Portland, OR) was used to validate MS/MS-based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than 90.0% probability as specified by the Peptide Prophet algorithm (18). Protein identifications were accepted if they could be established at greater than 95.0% probability and contained at least two identified peptides. Protein probabilities were assigned by the Protein Prophet algorithm (19).

One-dimensional SDS-PAGE Analysis and Western Blotting—For one-dimensional electrophoresis, samples containing 10 μg of protein were mixed with Laemmli sample buffer (1:1 ratio) and loaded onto 10% SDS-polyacrylamide gels. Gels were transferred onto a Protran nitrocellulose membrane for Western blotting. The following antibodies were used: CD9 (1:500 dilution; clone MM2/57, Chemicon International), RAB5A (1:200 dilution; clone FL-215, Santa Cruz Biotechnology, Santa Cruz, CA), RAB11A (1:100 dilution; Invitrogen), hepatocyte growth factor-regulated tyrosine kinase substrate (HGS; previously known as HRS; 1:500 dilution; Alexis Biochemicals, San Diego, CA), GAPDH (1:500 dilution; clone 7B, LabFrontier, Seoul, Korea), ENO1 (1:1000 dilution; clone H300, Santa Cruz Biotechnology), 14-3-3 (1:1000 dilution; clone 3B9, Calbiochem, San Diego, CA), PSA (1:500 dilution; clone A0562, DakoCytomation), proteasome α subunits 6, 2, 4, 5, 1, and 3 (1:2000 dilution; clone MCP231, Biomol International), PSMA1 (1:1000 dilution; clone MCP20, Biomol International), PSMA3 (1:1000 dilution; clone MCP23, Biomol International), and proteasome subunit β1 (PSMB1; β1 according to the Baumeister et al. (20) nomenclature; Biomol International).

Isolation and Analysis of Exosomal RNA—Exosomal total RNA was isolated using the RNeasy Mini kit (Qiagen, Hilden, Germany) as described by Valadi et al. (16). In short, pelletted exosomes were disrupted and homogenized in 350 μl of buffer RLT (Qiagen), and 1050 μl of 100% ethanol was added before samples were transferred to the RNeasy Mini spin column. Hereafter the procedure was followed as described by the manufacturer’s protocol.

Analysis of RNA expression was performed by RT-PCR. One microgram of exosomal RNA was reverse transcribed using Moloney murine leukemia virus reverse transcriptase (Invitrogen) and an oligo (dT)12 primer. Primer combinations used were as follows: PSA-4A (5'-AGCTGTGCTGAAGCTTCCG-3') and PSA-5B (5'-TGTACAGG-GAGGCTTTTCG-3'), TMPRSS2-E1 (5'-AGCAGCGGAGGAAGCCTTA-3') and ERG-R (5'-CATGGAGAATGATCCTAAAAGAGCTG-3'), and GAPDH 462U17 (5'-ACTGTTGCTATGGTG-3') and GAPDH 589L20 (5'-ACTGTTGCTATGGTG-3'), PCR was performed for 27 cycles at an annealing temperature of 58 °C.

Identification of 44 Tumor-derived Proteins in Xenografted Mice—The selection procedure followed to annotate identified proteins as tumor-derived in the circulation of human prostate cancer-xenografted mice is depicted in Fig. 1. After serum collection from control mice (n = 9) and PC346 (n = 9) and PC339 (n = 9) xenografted mice, samples were pooled and depleted of high abundance proteins, and proteins were separated by one-dimensional gel electrophoresis. Following tryptic digestion, peptides were subsequently analyzed by LTQ-FT-ICR-MS/MS. After data analysis (supplemental materials and methods), 44 proteins were identified as tumor-derived (at greater than 95.0% probability and with two or more identified peptides) (Table I). Of those, 22 were annotated as cytoplasmic proteins by the Gene Ontology database. The cytoplasmic proteins contained 12 of the subunits of the proteasome of which seven were identified based on the presence of human-specific peptides in the serum of xenograft-bearing mice.

Validation and Characterization of Proteasome Subunits in Xenograft Sera—To specify and validate the presence of tumor-derived proteasome subunits in the circulation of the xenografted mice, two-dimensional SDS-PAGE analysis of xenograft-derived serum samples was performed. Fig. 2 shows a comparison between serum from control mice (n = 3)
Table I
List of 44 proteins annotated as tumor-derived proteins in xenograft-bearing mice

Identified peptides were divided into a group of human specific peptides (identified only in the IPI human database) and a group of homologous peptides (present in both the IPI human and IPI mouse database). Homologous peptides were annotated as tumor-derived when 4 or more times higher abundant in the serum of PC339 or PC346 xenografted-mice in comparison with control serum. Annotations are derived from the Gene Ontology database.

| Protein name                  | Gene symbol | IPI accession no. | Human/homologue | No. of unique peptides | Sequence coverage | Xenograft | Molecular function | Biological process                               | Location               |
|-------------------------------|-------------|-------------------|-----------------|------------------------|-------------------|-----------|-------------------|-----------------------------------------------|------------------------|
| 14-3-3 protein γ             | YWHAG       | IPI00230707       | Homologue       | 5                      | 20.65             | PC339     | Protein kinase C binding | Regulation of signal transduction                | Cytoplasm             |
| 14-3-3 protein ι             | YWHAI       | IPI0018146        | Human           | 4                      | 15.92             | PC339     | Protein kinase C inhibitor activity | Regulation of progression through cell cycle     | Cytoplasm             |
| α-Enolase                     | ENO1        | IPI00465248       | Human           | 4                      | 26.67             | PC339     | Phosphofructokinase hydratase activity | Glycolysis             | Cytoplasm             |
| Apolipoprotein A-I precursor  | APOA1       | IPI0021841        | Human           | 3                      | 16.24             | PC339     | Lipid binding         | Cholesterol metabolism                        | Secreted               |
| Cathepsin Z precursor         | CTSS        | IPI00002776       | Homologue       | 2                      | 5.61              | PC339     | Osteine-type peptidase activity | Proteolysis             | Lysosome               |
| Chromosome 20 orf 114         | C20orf114   | IPI00291410       | Human           | 2                      | 4.34              | PC339     | Lipid binding         | Blood coagulation                              | Secreted               |
| Coactosin-like protein        | COTL1       | IPI00017704       | Homologue       | 2                      | 9.15              | PC339     | Actin binding         | Cytoskeleton organization and biogenesis        | Cytoplasm             |
| Coflin, non-muscle isoform a  | CFL1        | IPI00102101       | Homologue       | 3                      | 21.69             | PC339     | Protein binding       | Cell adhesion                                  | Cytoplasm             |
| Complement component C8 β chain precursor | C8B | IPI00294395 | Homologue | 2 | 5.66 | PC339 |
| Cytochrome c                  | CYCS        | IPI00465315       | Homologue       | 2                      | 17.14             | PC346/339 | Heme binding         | Caspase activation via cytochrome c                | Mitochondrial matrix |
| Fructose-bisphosphatase       | ALDOA       | IPI00465394       | Human/ Homologue | 11                     | 30.77             | PC346/339 | Fructose-bisphosphatase aldolase activity | Glycolysis             |                     |
| Glutathione peroxidase 3      | GPX3        | IPI00026199       | Human           | 5                      | 23.01             | PC339     | Glutathione peroxidase activity | Hydrogen peroxide catabolism                     | Secreted               |
| Glyceraldehyde-3-phosphate    | GAPDH       | IPI00219018       | Human           | 7                      | 25.97             | PC346/339 | Glyceraldehyde-3-phosphate dehydrogenase activity | Cytoskeleton organization and biogenesis        | Cytoplasm             |
| Inter-α (globulin) inhibitor H3| ITIH3       | IPI0028413        | Homologue       | 2                      | 3.03              | PC346     | Serine-type endopeptidase inhibitor activity | Hyaluronan metabolism                         | Secreted               |
| Junction plakoglobin          | JUP         | IPI00554711       | Homologue       | 2                      | 2.81              | PC339     | Cytoskeletal protein binding | Cell adhesion                                  | Cell membrane          |
| Lactate dehydrogenase A*      | LDHA        | IPI00217966       | Human/ Homologue | 9                      | 21.69             | PC346/339 | L-Lactate dehydrogenase activity | Anaerobic glycolysis                         | Cytoplasm             |
| Lactate dehydrogenase B*      | LDHB        | IPI00219217       | Human           | 10                     | 29.94             | PC346/339 | L-Lactate dehydrogenase activity | Anaerobic glycolysis                         | Cytoplasm             |
| Lumican precursor             | LUM         | IPI0020986        | Homologue       | 2                      | 5.92              | PC339     | Collagen binding      | Collagen fibril organization                    | Secreted               |
| Lysozyme C precursor          | LYZ         | IPI0019038        | Human/ Homologue | 4                      | 23.65             | PC346/339 | Lysozyme activity     | Inflammatory response                           | Cell membrane          |
| Maltase-glucoamylase, intestinal a | MGAM | IPI00220143 | Human | 3 | 1.18 | PC346/339 | Protein binding | Carbohydrate metabolism |
| Myosin heavy chain, skeletal muscle, adult 2 | MYH2 | IPI0007856 | Homologue | 3 | 4.94 | PC346 | Actin binding | Muscle filament sliding |
| Myosin, light polypeptide 6, non-muscle isoform 1 | MYL6B | IPI00335168 | IPI00413922 | 3 | 14.42 | PC339 | Structural component of muscle | Muscle filament sliding |
| Nucleoside-diphosphate kinase A | NME1    | IPI0012048       | Human/ Homologue | 6                      | 46.71             | PC339     | Nucleoside-diphosphate kinase activity | Negative regulation of cell proliferation       | Cytoplasm             |
| Nucleoside-diphosphate kinase B | NME2    | IPI00026260      | Homologue       | 6                      | 42.76             | PC339     | Nucleoside-diphosphate kinase activity | Negative regulation of cell proliferation       | Cytoplasm             |
| Protein name                     | Gene symbol | IPI accession no. | Human/homologue | No. of unique peptides | Sequence coverage | Xenograft | Molecular function                  | Biological process         | Location |
|---------------------------------|-------------|------------------|-----------------|------------------------|------------------|-----------|-------------------------------------|---------------------------|----------|
| Peroxiredoxin-2<sup>a</sup>     | PRDX2       | IPI00000874      | Human/homologue | 3                      | 13.13            | PC339     | Thioredoxin peroxidase activity     | Antiapoptosis              | Cytoplasm |
| Proteasome subunit α type 1     | PSMA1       | IPI000472442     | Human/homologue | 6                      | 24.91            | PC346/339 | Peptidase activity                 | Proteolysis               | Cytoplasm |
| Proteasome subunit α type 2     | PSMA2       | IPI00219622      | Homologue       | 5                      | 22.64            | PC346/339 | Peptidase activity                 | Proteolysis               | Cytoplasm |
| Proteasome subunit α type 4     | PSMA4       | IPI00299155      | Human           | 5                      | 17.30            | PC339     | Peptidase activity                 | Proteolysis               | Cytoplasm |
| Proteasome subunit α type 6     | PSMA6       | IPI00029623      | Homologue       | 9                      | 37.80            | PC346     | Peptidase activity                 | Proteolysis               | Cytoplasm |
| Proteasome subunit α type 7     | PSMA7       | IPI00024175      | Human           | 6                      | 21.37            | PC339     | Peptidase activity                 | Proteolysis               | Cytoplasm |
| Proteasome subunit β type 1     | PSMB1       | IPI00025019      | Human/homologue | 7                      | 34.02            | PC346/339 | Peptidase activity                 | Proteolysis               | Cytoplasm |
| Proteasome subunit β type 2     | PSMB2       | IPI00028006      | Homologue       | 2                      | 12.44            | PC346     | Peptidase activity                 | Proteolysis               | Cytoplasm |
| Proteasome subunit β type 3<sup>a</sup> | PSMB3 | IPI00028004      | Homologue       | 3                      | 18.05            | PC346/339 | Peptidase activity                 | Proteolysis               | Cytoplasm |
| Proteasome subunit β type 4     | PSMB4       | IPI000556607     | Human/homologue | 5                      | 17.80            | PC346/339 | Peptidase activity                 | Proteolysis               | Cytoplasm |
| Proteasome subunit β type 5     | PSMB5       | IPI000479306     | Human/homologue | 10                     | 38.78            | PC346/339 | Peptidase activity                 | Proteolysis               | Cytoplasm |
| Proteasome subunit β type 6     | PSMB6       | IPI00000811      | Human           | 3                      | 12.97            | PC346/339 | Peptidase activity                 | Proteolysis               | Cytoplasm |
| Proteasome subunit β type 8     | PSMB8       | IPI00000783      | Homologue       | 2                      | 5.88             | PC346     | Protein binding                    | Proteolysis               | Cytoplasm |
| Prothrombin precursor           | F2          | IPI00019568      | Homologue       | 2                      | 2.25             | PC346     | Thrombin activity                  | Regulation of progression through cell cycle | Secreted |
| Splice isoform 1 of complement factor B precursor | CFP | IPI00639937      | Homologue       | 2                      | 4.90             | PC346/339 | Complement binding                 | Complement activation     | Secreted |
| Thrombospondin-1 precursor<sup>a</sup> | THBS1 | IPI000296099     | Homologue       | 7                      | 7.26             | PC346/339 | Signal transducer activity         | Cell motility              | Secreted |
| Transcobalamin-2                | TC2         | IPI00136556      | Homologue       | 3                      | 6.09             | PC339     | Cobalamin transporter activity     | Cobalamin transport       | Secreted |
| Triose-phosphate isomerase 1 variant<sup>a</sup> | TPI1 | IPI000465028     | Human/homologue | 5                      | 22.09            | PC346/339 | Triose-phosphate isomerase activity | Glycolysis                |          |
| Voltage-dependent anion channel 2 | VDAC2 | IPI00455531      | Homologue       | 2                      | 7.77             | PC346     | Voltage-gated anion channel porin activity | Anion transport           | Mitochondrion outer membrane |

<sup>a</sup> Proteins that have earlier been identified by others in isolated exosomes from various origin.
and serum from PC339 (n = 3) and PC346 (n = 3) xenografted mice. Proteasome subunits were detected using a monoclonal antibody directed against α subunits 6, 2, 4, 5, 1, and 3 of the proteasome. Strong signals were observed in the serum from both the PC346 and PC339 xenografted mice. As the proteasome antibody recognizes both mouse and human proteasome subunits, also faint signals were visible in the control serum that are known to be normally present in the mouse circulation. This is in line with the identification of mouse-specific proteasome peptides as detected by FT-ICR-MS/MS (data not shown). After stripping, blots were reprobed, and two of the spots could be specifically identified in the serum of PC339 and PC346 xenografted mice as the PSMA1 and PSMA3 subunits by using specific monoclonal antibodies directed against these proteins. The identified spots were consistent regarding molecular weight and pl with an earlier study performed by Claverol et al. (26).

Proteasome Subunits Are Circulating as a Complex in Xenograft Sera—To investigate whether the identified proteasome subunits were present as proteasome complexes in the serum of xenografted mice, native gel electrophoresis of control serum and serum from xenograft-bearing mice was performed. Fig. 3a shows the presence of high molecular weight proteasome complexes in the xenograft sera. In both the 12.5% gel and 3.5% gel high molecular weight complexes are visible in the samples that were run under native conditions. After denaturation, the high molecular weight complexes disappeared, indicating disintegration into single proteasome subunits. The same effect is seen in the endogenous proteasome subunits of the control mouse.

The presence of intact proteasome complexes was also investigated by sandwich ELISA. Serum samples from control

![Fig. 2. 2D PAGE Western blotting analysis of depleted serum from control mice (CM), PC346 xenograft-bearing mice (PC346), and PC339 xenograft-bearing mice (PC339). Spots were detected by using a monoclonal antibody to proteasome α subunits 6, 2, 4, 5, 1, and 3. The presence of PSMA1 and PSMA3 proteasome subunits was confirmed with specific monoclonal antibodies. Strong signals are visible in the serum from both the PC346 and PC339 mice. Also faint signals were detected in the control serum because of cross-reactivity with mouse proteasome subunits, which are present under normal conditions in the mouse serum.](image)

![Fig. 3. a, native 1D gel electrophoresis of serum from control mice (CM) and PC346 or PC339 xenograft-bearing mice showing the presence of intact proteasome complexes. High molecular weight complexes are visible under native conditions in both 12.5 and 3.5% gels. After denaturation, mostly single subunits are visible in the 12.5% gel, and the high molecular weight complexes in the 3.5% gel have disappeared. Bands were detected by a monoclonal antibody directed against the PSMA1 subunit of the proteasome. b, proteasome concentrations in xenograft-bearing mice and control mice serum samples under native (left) and denatured (right) conditions as measured by sandwich ELISA. After serum denaturation proteasome levels are strongly diminished, indicating the existence of proteasome complexes in xenograft and control serum samples. Error bars represent standard deviations.](image)
(n = 3) and xenograft mice (n = 6) were diluted 1:20 and analyzed in triplicate under native conditions and after denaturation by heating at 96 °C for 5 min. Proteasome levels (mean ± S.D.) under native conditions in control, PC346, and PC339 serum were 10.5 ± 10.6, 32,759 ± 1720.0, and 20,339 ± 5062.2 ng/ml, respectively. After denaturation, proteasome concentrations (mean ± S.D.) decreased to 0.040 ± 0.03, 0.17 ± 0.16, and 0.28 ± 0.10 ng/ml in control, PC346, and PC339 serum, respectively (Fig. 3b). Because the capture antibody of the sandwich ELISA is directed against the 1 subunit (PSMA1) of the proteasome whereas the detection antibody is directed against subunits, this confirms the presence of proteasome complexes in the serum of the xenografted mice.

Electron Microscopy of Isolated Exosomes—A large portion of the cytoplasmic tumor-derived proteins identified in the xenograft model has previously been identified as part of the human exosomal protein content. To explore the origin of the cytoplasmic proteins identified in the xenograft serum, exosomes were isolated from the PC346C cell line. To confirm that the structures isolated were indeed exosomes, they were examined by electron microscopy (Fig. 4a). This showed a homogenous mixture of small bilayer membrane vesicles with an average diameter of 140 nm. ImmunoGold labeling of exosomes with an antibody to CD9 (Tetraspanin 29), an established marker for tumor cell-derived exosomes, showed positive exosome membrane staining (Fig. 4a).

Proteomics Analysis of Exosomes—Supernatant and exosome fractions of the PC346C cell line were separated by 1D SDS-PAGE followed by silver staining (Fig. 4b). The exosome fractions showed several distinct bands, which were absent in the supernatant fraction. Several bands were excised and subjected to LTQ-Orbitrap mass spectrometry (MS/MS) leading to the identification of five proteins: programmed cell death 6 protein (PDCD6IP; 10 unique peptides, 10.65% sequence coverage), poly(A)-binding protein 1 (PABC1; 12 unique peptides, 18.71% sequence coverage), eukaryotic translation elongation factor 1-α (EEF1A1; three unique peptides, 6.28% sequence coverage), -actin-2 (ACTA2; 13 unique peptides, 45.62% sequence coverage), and syndecan-binding protein (syntenin; four unique peptides, 14.77% sequence coverage).

An in-depth proteomics analysis of the whole exosome fraction was performed by LTQ-FT-ICR-MS/MS. A total of 48 unique proteins were discovered in the exosome fraction of the PC346C cell line at a protein identification probability of ≥99% and ≥2 peptides per protein (Table II). At a protein probability of ≥99% and ≥1 peptide per protein 126 proteins were identified. Among those proteins identified with two or more peptides per protein were two of the proteins that had earlier been identified in the serum of xenograft-bearing mice (GAPDH and lactate dehydrogenase B) (12). Also the presence of the exosomal marker CD9 and the prostate-specific protein folate hydrolase 1 (FOLH1; prostate-specific membrane antigen) were confirmed. ENO1 and fructose-bisphos-
**TABLE II**

List of 48 proteins identified by two or more peptides in the exosome fraction of the PC346C cell line. Annotations are derived from the Gene Ontology database.

| Protein name                                      | Gene symbol | Protein accession no. | No. of unique peptides | Sequence coverage | Molecular function | Biological process | Location          |
|---------------------------------------------------|-------------|-----------------------|------------------------|-------------------|--------------------|--------------------|-------------------|
| Actin, γ 1                                         | ACTG1       | IPI00021440           | 15                     | 40.30             | Structural constituent of cytoskeleton | Cell motility   | Cytoplasm         |
| ADAM metalloproteinase domain 10                  | ADAM10      | IPI00013897           | 3                      | 3.88              | Protein homodimerization activity   | Protein amino acid phosphorylation | Cell membrane |
| ADAM metalloproteinase domain 15                  | ADAM15      | IPI00013302           | 4                      | 6.39              | Proteolytic and peptidolytic activity | Cell adhesion | Cell membrane     |
| Annexin A2                                         | ANXA2       | IPI00418169           | 7                      | 24.90             | Phospholipase inhibitor activity   | Skeletal development | Secreted protein |
| Annexin A6                                         | ANXA6       | IPI00002459           | 3                      | 7.20              | Calcium ion binding               |                     |                   |
| ATPase, Na+/K+-transporting, α 1 polypeptide       | ATP1A1      | IPI00006482           | 5                      | 5.96              | Sodium-potassium-exchanging ATPase activity | Sodium ion transport | Cell membrane |
| Brain-abundant, membrane-attached signal protein 1 | BASP1       | IPI00299024           | 4                      | 40.10             |                               |                     |                   |
| Chromosome 1 open reading frame 58                | C1orf58     | IPI00065500           | 2                      | 10.70             |                               |                     |                   |
| Capping protein (actin filament) muscle Z-line, α 1 | CAPZA1      | IPI00006482           | 2                      | 7.69              |                               |                     |                   |
| CD151 molecule (Tetraspanin 24)                   | CD151       | IPI00298851           | 2                      | 5.93              |                               |                     |                   |
| CD2-associated protein                            | CD2AP       | IPI00412771           | 6                      | 11.60             | Structural constituent of cytoskeleton | Cell migration | Cytoplasm         |
| CD9 molecule                                      | CD9         | IPI000215997          | 3                      | 15.40             |                               | Cell motility     |                   |
| Chromatin-modifying protein 4B                    | CHMP4B      | IPI00025974           | 2                      | 8.93              |                               | Cytoplasm         |                   |
| Clathrin, heavy chain 1                           | CLTC        | IPI00024067           | 10                     | 6.81              | Signal transducer activity        | Receptor-mediated endocytosis | Cell membrane |
| Eukaryotic translation elongation factor 1 α 1    | EEF1A1      | IPI00396485           | 14                     | 37.20             | Translation elongation factor activity | Translation elongation | Cytoplasm         |
| EH domain-containing protein 1                    | EHD1        | IPI00017184           | 2                      | 5.06              | ATP binding                      |                     |                   |
| F11 receptor                                      | F11R        | IPI00001754           | 5                      | 16.40             |                               | Cell motility     |                   |
| Family with sequence similarity 125, member A     | FAM125A     | IPI00744702           | 3                      | 16.10             |                               | Cytoplasm         |                   |
| Formin-binding protein 1-like                     | FNBP1L      | IPI00015580           | 2                      | 3.47              | Dipeptidase activity             | Proteolysis       |                   |
| Folate hydrolase (prostate-specific membrane antigen) 1 | FOLH1     | IPI00028514           | 7                      | 12.30             |                               |                     |                   |
| Glyceraldehyde-3-phosphate dehydrogenase          | GAPDH       | IPI00219018           | 3                      | 14.00             | Glyceraldehyde-3-phosphate dehydrogenase activity | Glycolysis       | Cytoplasm         |
| Histone cluster 1, H1c                            | HIST1H1C    | IPI00217465           | 2                      | 10.30             | DNA binding                      | Nucleosome assembly | Nucleus           |
| Histone cluster 1, H2ab                           | HIST1H2AB   | IPI00026272           | 2                      | 21.50             | DNA binding                      | Nucleosome assembly | Nucleus           |
| Heat shock protein 90 kDa α (cytosolic), class B member 1 | HSPA9A   | IPI00334775           | 4                      | 6.49              | Unfolded protein binding         | Response to unfolded protein | Cytoplasm         |
| Heat shock 70-kDa protein 1B                       | HSPA1B      | IPI00807640           | 6                      | 16.50             | Unfolded protein binding         | Antiapoptosis     | Cytoplasm         |
| Heat shock 70-kDa protein 8                        | HSPA8       | IPI00003865           | 13                     | 25.50             | ATPase activity                  | Protein folding    |                   |
| Immunoglobulin superfamily, member 8              | IGSF8       | IPI00056478           | 12                     | 6.12              | Protein binding                  | Cell motility     |                   |
| Integrin β-1                                      | ITGB1       | IPI00217563           | 3                      | 3.89              | Protein heterodimerization activity | Cell migration    |                   |
| Lactate dehydrogenase B                           | LDHB        | IPI00219217           | 2                      | 7.78              | L-Lactate dehydrogenase activity | Anaerobic glycolysis | Cytoplasm         |
| Milk fat globule-EGF factor 8 protein              | MFGE8       | IPI00002236           | 2                      | 4.91              |                               | Cell adhesion     |                   |
| Poly(A)-binding protein, cytoplasmic              | PABPC1      | IPI00008524           | 16                     | 25.90             | Translation activator activity    | mRNA stabilization | Cytoplasm         |
| Poly(A)-binding protein, cytoplasmic              | PABPC4      | IPI00555747           | 5                      | 18.40             | Protein/RNA binding              | RNA processing    |                   |
| Protein kinase C and casein kinase substrate in neurons 2 | PACSN2     | IPI00027009           | 4                      | 8.85              | Transporter activity             | Intracellular protein transport | Cytoplasm         |
| Poly(C)-binding protein 2                         | PCB2P       | IPI00012066           | 2                      | 7.46              | Protein/RNA binding              | mRNA metabolic process | Cytoplasm         |
| Programmed cell death 6-interacting protein       | PDCD6I      | IPI00246058           | 21                     | 22.40             | Signal transducer activity       | Apoptosis         |                   |
| Prostaglandin F2 receptor negative regulator      | PTGFRN      | IPI00022048           | 7                      | 9.33              | Protein binding                  | Negative regulation of protein biosynthetic process | Cell membrane |
phate aldolase A, also previously identified in the serum of xenograft-bearing mice, were positively identified at a probability of one peptide per protein (data not shown). All proteins identified in the specific exosome bands but ACTA2 (Fig. 4b) were also recovered in the in-depth proteomics analysis.

Analysis of Exosomes by One-dimensional SDS-PAGE

Analysis—One-dimensional SDS-PAGE and Western blotting were performed to verify the presence in exosomes of several proteins previously identified by LTQ-FT-ICR-MS/MS in the xenograft model. CD9, RAB5A, RAB11A, HRS, GAPDH, and 14-3-3 protein (YWHAQ) were uniquely present in the isolated exosome fraction and could not be detected in the PC346C cell line supernatant, whereas α-enolase (ENO1) and subunits of the proteasome were present in both fractions. PSA was uniquely present in the supernatant fraction and could not be detected in the isolated exosomes (Fig. 5a).

To certify that the proteasome subunits present in the exosome fraction were not the result of simultaneous pelleting of exosomes and proteasome complexes during ultracentrifugation, exosomes were further purified by magnetic beads coated with a CD9 antibody. After exosomal purification, bead-exosome complexes were loaded onto one-dimensional SDS-polyacrylamide gels. Blots were incubated with a monoclonal antibody to CD9 (Chemicon International) or a polyclonal antibody against the PSMB1 subunit of the proteasome. Fig. 5b shows that both the CD9 and PSMB1 subunit signals are visible in the exosome fraction as well as in the immunobead-purified exosome fraction.

Analysis of Exosomal RNA—As the PCa-specific TMPRSS2-ERG gene fusion is expressed in the majority of PCa patients, we analyzed exosomes for the presence of the gene fusion product (27, 28). RNA was isolated from PC346C and VCaP cells and analyzed by RT-PCR. Both cell lines express PSA, whereas the TMPRSS2-ERG gene fusion is only present in VCaP and not in PC346 cells (27). KLK3 (PSA) and GAPDH RNAs were present in both VCaP and PC346C exosomes as well as in the total RNA fraction from both cell lines. The gene fusion product TMPRSS2-ERG was only detected in VCaP exosomes and in the VCaP cell line and was not detected in PC346C-derived exosomes and the PC346C cell line (Fig. 6).

DISCUSSION

The present study shows the identification of 44 tumor-derived proteins by mass spectrometry in xenograft models for PCa. Virtually all subunits of the proteasome were among the proteins identified, a finding that was verified by two-dimensional gel electrophoresis of xenograft-bearing and control mouse sera. Several of these proteasome subunits are part of the normal human plasma proteome as was shown by the Human Proteome Organisation Plasma Proteome Project (13). Increased proteasome levels have been related to hematologic malignancies, especially multiple myeloma (29), but also to solid tumors, such as melanoma and colon carcinoma (30). Recently Byrne et al. (31) identified the proteasome β6
subunit in a proteomics analysis of serum from patients with
PCa. Abnormal gene expression of proteasome subunits has
been reported in several cancer types (29, 32). High plasma
proteasome levels reflect the dysregulation of protein syn-
thesis and degradation in cancer cells in contrast to normal
cells in which the proteasome complex plays a crucial role
in controlling essential cellular functions such as transcrip-
tion, stress response, cell cycle regulation, cellular differenti-
ation, and DNA repair (33). This is also illustrated by the
fact that in malignancies proteasome inhibitors induce apo-
ptosis, have in vivo antitumor efficacy, and sensitize malig-
nant cells for conventional therapies (33).

The secretion mechanism of circulating proteasomes in
cancer patients and healthy donors is still unknown. Elevated
proteasome concentrations in culture media of human leuke-
mic cell lines have been reported, suggesting a proteasome
secretion mechanism by tumor cells (34). In this study, we
have shown, using native gel electrophoresis and sandwich
ELISA of sera from xenografted and control male mice, that at
least part of the circulating proteasome subunits are present
as proteasome complexes. This is in line with the observation
that circulating proteasomes are intact and enzymatically ac-
tive in plasma from healthy donors and patients with autoim-
mune disease or leukemia (35, 36).

About half of the tumor-derived proteins circulating in the
xenograft-bearing mice, including proteasome subunits, are
not secreted proteins but are annotated as being cytoplasmic.
One possible explanation for their presence could be the
occurrence of necrosis or apoptosis in the xenografts, a well
known characteristic of most cancers. Although we did not
find evidence for necrosis in the xenografts used for this
study, protein secretion via cell death cannot be excluded.
Microarray expression data of the identified cytoplasmic pro-
teins showed that these indeed corresponded to genes that
are highly expressed in PCa. However, none of the proteins of
the 100 most highly expressed genes in PCa (such as ribo-
somal and cytoskeletal genes) have been identified in the
circulation of the xenograft-bearing mice (data not shown).

One would expect to detect the proteins of these highly

Fig. 5. a, 1D PAGE and Western blotting analysis comparing the
exosome and supernatant fractions of the PC346C cell line for CD9,
the members of the RAS oncogene family RAB5A and RAB11A, HRS,
GAPDH, ENO1, YWHAQ (14-3-3 protein), proteasome α subunits,
and PSA. CD9, RAB5A, RAB11A, HRS, GAPDH, and YWHAQ were
uniquely identified in the isolated exosomes, whereas PSA could only
be detected in the supernatant of the PC346C cell line. b, 1D PAGE
and Western blotting analysis of the exosome fraction after purifi-
cation with magnetic beads. This figure shows that the CD9 and pro-
teasome α1 (PSMB1) signals are visible in the exosome fraction both
before and after purification with magnetic beads, indicating that
proteasome subunits are present inside exosomes or exosomal
membranes.

Fig. 6. RT-PCR analysis of VCaP and PC346C cell lines and
exosomes. The TMPRSS2-ERG fusion gene is exclusively expressed
in both the VCaP cell line and exosomes, whereas both cell lines and
exosomes express KLK3 (PSA) and GAPDH. H2O and -RT controls
were negative (data not shown).
expressed genes if these are the result of tumor apoptosis. Although this does not rule out the contribution of apoptosis or necrosis, this points toward certain specific processes responsible for the secretion of cytoplasmic proteins.

We hypothesized that one such specific process could be the secretion of proteins via exosomes. A literature search revealed that 13 of the 44 (30%) identified proteins in the xenograft model had earlier been identified in exosomes among which was also the β3 subunit of the proteasome (Table I). First, we showed that the human PCa cell line PC346C is indeed capable of the secretion of exosomes (Fig. 4a). Second, LTQ-FT-ICR-MS/MS and Western blotting analyses of isolated exosomes showed the presence of mainly cytoplasmic proteins, including GAPDH, fructose-bisphosphate aldolase A, ENO1, lactate dehydrogenase B, 14-3-3 protein α, and proteasome subunits (see Table II and Fig. 5a).

To argue against the fact that the proteasome signal in the exosome fraction was the result of simultaneous pelleting of exosomes and proteasome complexes, exosomes were further purified by immunoaffinity precipitation utilizing anti-CD9 antibody-coated magnetic beads. This strengthened our finding that proteasomes are present inside exosomes and/or tightly associated with exosomal membranes or external macromolecules. Our observation is in agreement with Almeida et al. (37) and Dong et al. (38) who showed the presence of proteasomes in late endosomes from which exosomes are formed by invagination and budding. To our knowledge, the present study is the first to describe a specific clearance mechanism for proteasome subunits in cancer cells, providing a possible explanation for the increased proteasome serum levels that have been observed in several types of cancer patients.

An important observation is that PSA was not detectable in the exosome pellets but was abundant in the supernatant. This means that we experimentally separated protein secretion via two different secretion pathways: (i) the typical secretion of signal peptide-containing proteins via the rough endoplasmic reticulum and Golgi apparatus secretory pathway and (ii) the multivesicular body-exosome secretion route. This is in line with our observation that of a total of 48 proteins identified in the exosome fraction the majority are annotated as cytoplasmic whereas only two proteins are annotated as secreted according to the Gene Ontology database. In contrast, 10 of 44 tumor-derived proteins identified in the serum of xenograft-bearing mice are annotated as secreted proteins (Tables I and II). Thus, it seems that several of the cytoplasmic proteins, including proteasome subunits, present in xenograft sera are at least partly secreted via the exosome pathway in contrast with proteins such as PSA that are typically secreted via the Golgi consecutive secretory pathway.

The putative in vivo analogues of exosomes could be prostasomes, secreted vesicles in human seminal fluid, secreted by epithelial prostate cells. Proteomics analysis of human prostasomes revealed 139 proteins, showing a small overlap (7 of 139) with the proteins identified in exosomes in the present study. Among the proteins identified in prostasomes were several glycolysis-related enzymes, heat-shock proteins, and proteins of the annexin family (39). In contrast, no proteasome subunits or members of the tetraspanin family were identified in prostasomes isolated from seminal fluid.

It was recently reported by Valadi et al. (16) that exosomes not only contain proteins but also mRNAs, suggesting a potential novel mechanism of genetic exchange between cells. By RNase and trypsin treatment of the isolated exosomes it was confirmed that the mRNA was indeed confined within exosomes and not on external structures or macromolecules. This prompted us to isolate exosomal RNA from the PC346C and VCaP cell lines. Of these cell lines it has been shown that the VCaP cell line expresses the TMPRSS2-ERG fusion gene, whereas PC346C does not (27, 28). RT-PCR analysis correctly showed that the PCa-specific TMPRSS2-ERG fusion gene is present in exosomal RNA from the VCaP cell line whereas it is absent in exosomal RNA from the PC346C cell line. As it has been reported that exosomes exist in human serum, prostate-specific proteins present in the membrane of exosomes, such as FOLH1, could be used to isolate prostate-specific exosomes to discover and validate new markers for PCa (40). For example, this could lead to the development of a serum test for RNA transcribed from the TMPRSS2-ERG gene fusion.

The specific role of exosomes in cancer is still not fully understood, and involvement in processes such as cell-cell communication and antigen representation have been suggested (14–16). The content of exosomes may represent a fingerprint of the cytoplasm of the cancer cell and may establish a unique environment that allows for the occurrence of specific processes. For example, Stoeck et al. (41) showed that exosomes may be a platform for ectodomain shedding of transmembrane proteins. In the present study, the presence of a distinct 30-kDa ENO1 band specifically present in the exosome fraction may point toward the occurrence of unique proteolytic activity inside exosomes (Fig. 5a). It has recently been suggested that exosomes secreted from cancer cells support immune escape as well as tumor growth (15). Also exosomes have been reported to induce angiogenesis and to transfer metastatic activity from highly to poorly metastatic tumor cells (42). Of the proteins identified in the exosomes in the present study, CD151 and the metalloproteinases ADAM10 and ADAM15 have been linked to tumor invasive-
Exosomes Secrete Cytoplasmic Prostate Cancer Proteins

ness and prognosis (43–45). The proteasomes identified in exosomes may harbor a similar function.

In conclusion, the present study shows that, although their function is unclear, exosomes offer unique possibilities for PCA biomarker discovery as they give insight information about the interior of the cancer cell both on the protein and RNA levels. Further studies will focus on the validation of several identified exosomal proteins as well as on the detection of exosomal RNA, including the TPMPRSS2-ERG and other gene fusion transcripts in exosomes isolated from patient populations, to establish new biomarkers for PCA diagnosis and prognosis.

Acknowledgments—We are indebted to Dr. Irmgard Schwarte-Waldhoff (Department of Internal Medicine, Immunologisch-Molekularbiologisches Labor, Knappschaftskrankenhaus, University of Bochum, Bochum, Germany) and Dr. Hans Romijn (Department of Urology), and Dr. Joost Hegmans (Department of Pulmonary Medicine) for technical assistance and advice.

* This work was supported by the Netherlands Genomics Initiative (Horizon Breakthrough Project 050-71-106), the Netherlands Proteomic Centre, and the Adessium Foundation.

** To whom correspondence should be addressed: Dept. of Urology, Josephine Nefkens Inst., Erasmus MC, Rm. Be362a, P. O. Box 2040, 3000 CA Rotterdam, The Netherlands. Tel.: 31-10-704-3672; Fax: 31-10-704-4661; E-mail: g.jenster@erasmusmc.nl.

REFERENCES

1. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., and Redwine, E. (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909–916
2. McCauley, C., Lee, J., Fulton, J. P., Tonita, J., and Thompson, T. D. (2004) Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep. 119, 174–186
3. Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., Crowley, J. J., and Coltman, C. A., Jr. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliters. N. Engl. J. Med. 350, 2239–2246
4. Mikolajczyk, S. D., and Rittenhouse, H. G. (2004) Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease. Rinsho Byori 52, 223–230
5. Paul, B., Dhir, R., Landsittel, D., Hitchens, M. R., and Getzenberg, R. H. (2005) Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res. 65, 4097–4100
6. Reiter, R. E., Gu, Z., Watabe, T., Thomas, G., Szigeti, K., Davis, E., Wahl, M., Nisitani, S., Yamashiro, J., Le Beau, M. M., Lodis, M., and Witte, O. N. (1998) Prostate stem cell antigen: a cell surface marker overexpressed in adenocarcinoma of the prostate. Proc. Natl. Acad. Sci. U. S. A. 95, 1735–1740
7. Rubin, M. A., Zhou, M., Dhanasekaran, S. M., Varambally, S., Bostwick, D., Sinha, P., Schroeck, D., and Loening, S. A. (2000) Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol. Biomark. Prev. 9, 1133–1147
8. de Kok, J. B., Verhaegh, G. W., Roelofs, R. W., Hessels, D., Kinneman, L. A., Aalders, T. W., Swinkels, D. W., and Schalken, J. A. (2002) DD3/PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer

9. Kumar-Sinha, C., Tomlins, S. A., and Chinnaiyan, A. M. (2008) Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 8, 497–511
10. van Weerden, W. M., de Ridder, C. M., Verdaasdonk, C. L., Romijn, J. C., van der Kwast, T. H., Schroder, F. H., and van Steenbrugge, G. J. (1996) Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am. J. Pathol. 149, 1055–1062
11. van den Bemd, G. J., Krizgysvd, J., Luider, T. M., van Rijswijk, A. L., Demmers, J. A., and Jenster, G. (2006) Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. Mol. Cell. Proteomics 5, 1830–1839
12. Ommen, G. S., States, D. J., Adamski, M., Blackwell, T. W., Menon, R., Hermjakob, H., Apweiler, R., Haab, B. B., Simpson, R. J., Eddes, J. S., Karif, A. D., Mortiz, R. L., Chin, D. W., Rai, A. J., Admon, A., Aebersold, R., Eng, J., Hancock, W. S., Hafta, S. A., Meyer, H., Paik, Y. K., Yoo, J. S., Ping, P., Pounds, J., Adkins, J., Qian, X., Wang, R., Wasinger, V., Wu, C. Y., Zhao, X., Zeng, R., Archakov, A., Tsugita, A., Beer, I., Pandey, A., Pisano, M., Andrews, P., Tammen, H., Speicher, D. W., and Hanash, S. M. (2005) Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database.
13. Thy, C., Zitvogel, L., and Amigorena, S. (2002) Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2, 569–579
14. Valenti, R., Huber, V., Iero, M., Filippazi, P., Parmigiani, G., and Rivoltini, L. (2007) Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 67, 2912–2915
15. Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J. J., and Lotvall, J. O. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659
16. Marques, R. B., van Weerden, W. M., Erkens-Schulze, S., de Ridder, C. M., Bangma, C. H., Trapman, J., and Jenster, G. (2006) The human PC343 xenograft and cell line panel: a model system for prostate cancer progression. Eur. Urol. 49, 245–257
17. Kall, A., Nesiavzhiski, A., Keller, A., Eber, M., and Aebersold, R. (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74, 5383–5392
18. Nesiavzhiski, A. I., Keller, A., Kolker, E., and Aebersold, R. (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75, 4646–4658
19. Baumeister, W., Walz, J., Zuhl, F., and Seemuller, E. (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell 92, 367–380
20. Elsasser, S., Schmidt, M., and Finley, D. (2005) Characterization of the proteasome using native gel electrophoresis. Methods Enzymol. 398, 353–363
21. Dutaud, D., Aubry, L., Henry, L., Levieux, D., Hendli, K. B., Kuehn, L., Kall, A., Kolker, E., and Aebersold, R. (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74, 5383–5392
22. Nesiavzhiski, A. I., Keller, A., Kolker, E., and Aebersold, R. (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75, 4646–4658
23. Hegman, J. P., Bard, M. P., Hermens, A., Luider, T. M., Kleijmeer, M. J., Prins, J. B., Zitvogel, L., Burgers, S. A., Hoogsteden, H. C., and Lam, Brink, B. N. (2004) Characterization of the proteasome by translocation or androgen receptor-negative prostate cancer cells using mass spectrometry. Eur. Urol. 45, 1055–1062
24. Mortz, E., Krog, T. N., Voreum, H., and Gorg, A. (2001) Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ionization-time of flight analysis. Proteomics 1, 1359–1363
25. Claverol, S., Burlet-Schiltz, O., Girbal-Neuhauser, E., Garin, J. E., and Massrat, B. (2002) Mapping and structural dissection of human 20 S proteasome using proteomic approaches. Mol. Cell. Proteomics 1, 567–578
26. Hermans, K. G., van Marion, R., van Dekken, H., Jenster, G., van Weerden, W. M., and Trapman, J. (2006) TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative pros-

1204 Molecular & Cellular Proteomics 8.6
28. Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X. W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., and Chinnaiyan, A. M. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Cancer Res. 66, 10658–10663

29. Kumatori, A., Tanaka, K., Inamura, N., Sone, S., Ogura, T., Matsumoto, T., Tachikawa, T., Shin, S., and Ichihara, A. (1990) Abnormally high expression of proteasomes in human leukemic cells. Proc. Natl. Acad. Sci. U. S. A. 87, 7071–7075

30. Milano, A., Iaffaioli, R. V., and Caponigro, F. (2007) The proteasome: a worthwhile target for the treatment of solid tumours? Eur. J. Cancer 43, 1125–1133

31. Byrne, J. C., Downes, M. R., O’Donoghue, N., O’Keane, C., O’Neill, A., Fan, Y., Fitzpatrick, J. M., Dunn, M. J., and Watson, R. W. (2009) 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J. Proteome Res. 8, 942–957

32. Kanayama, H., Tanaka, K., Aki, M., Kagawa, S., Miyaji, H., Satoh, M., Okada, F., Sato, S., Shimbara, N., and Ichihara, A. (1991) Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res. 51, 6677–6685

33. Voorhees, P. M., Dees, E. C., O’Neil, B., and Orlowski, R. Z. (2003) The proteasome as a target for cancer therapy. Clin. Cancer Res. 9, 6316–6325

34. Wada, M., Kosaka, M., Saito, S., Sano, T., Tanaka, K., and Ichihara, A. (1993) Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiological significance. J. Lab. Clin. Med. 121, 215–223

35. Ma, W., Kantarjian, H., O’Brien, S., Jilani, I., Zhang, X., Estrov, Z., Ferrajoli, A., Keating, M., Giles, F., and Abbitt, M. (2008) Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer 112, 1306–1312

36. Zoeger, A., Blau, M., Egerer, K., Feist, E., and Dahlmann, B. (2006) Cultivating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells. Clin Chem. 52, 2079–2086

37. Almeida, C. G., Takahashi, R. H., and Gouras, G. K. (2006) β-Amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J. Neurosci. 26, 4277–4284

38. Dong, J., Chen, W., Welford, A., and Wandinger-Ness, A. (2004) The proteasome α-subunit XAPC7 interacts specifically with Rab7 and late endosomes. J. Biol. Chem. 279, 21334–21342

39. Utleg, A. G., Yi, E. C., Xie, T., Shannon, P., White, J. T., Goodlett, D. R., Hood, L., and Lin, B. (2003) Proteomic analysis of human prostates. Prostate 56, 150–161

40. Caby, M. P., Lankar, D., Vincendeau-Scherrer, C., Raposo, G., and Bonnerot, C. (2005) Exosomal-like vesicles are present in human blood plasma. Int. Immunol. 17, 879–887

41. Stocek, A., Keller, S., Riedle, S., Sanderson, M. P., Runz, S., Le Naour, F., Gutwein, P., Ludwig, A., Rubinstein, E., and Altevogt, P. (2006) A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. J. Am. Chem. Soc. 128, 609–618

42. Gao, S., Ye, Z., Li, F., Meng, Q., Qureshi, M., Yang, J., and Xiang, J. (2006) Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes. Exp. Oncol. 28, 126–131

43. Ginesa, A., La Placa, M. D., Saladino, F., Cassara, D., Nagase, H., and Vittorelli, M. L. (1998) The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasive- ness. Anticancer Res. 18, 3433–3437

44. Hashida, H., Takabayashi, A., Tokuhara, T., Hattori, N., Taki, T., Hasegawa, H., Satoh, S., Kobayashi, N., Yamaoka, Y., and Miyake, M. (2003) Clinical significance of transmembrane 4 superfamily in colon cancer. Br. J. Cancer 89, 158–167

45. Kuefer, R., Day, K. C., Kleer, C. G., Sabel, M. S., Hofer, M. D., Varambally, S., Zorn, C. S., Chinnaiyan, A. M., Rubin, M. A., and Day, M. L. (2006) ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia 8, 319–329